The purpose of the study is to verify the effectiveness and safety of Sulodexide in reducing the chances of VTE coming back in patients aged 75 years and older who have recently experienced a first episode of DVT or PE. The study will monitor the participants over a period to see if Sulodexide can lower the risk of new blood clots by 35% compared to the placebo. Additionally, the study will assess the safety of Sulodexide by checking for any major bleeding events, aiming to show that it is not inferior to the placebo in terms of safety.

Participants in the study will take either Sulodexide or the placebo orally, in the form of soft capsules. The trial will last for a maximum of 12 months, during which the health of the participants will be closely monitored to track any new episodes of VTE, overall mortality due to VTE, and any major bleeding incidents. The study aims to provide valuable information on the potential benefits and risks of using Sulodexide for preventing recurrent VTE in elderly patients.

The purpose of the study is to determine if taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already had a clot. Participants in the study will be randomly assigned to receive either Rosuvastatin Calcium or a placebo. The study will monitor the participants over a period of time to observe any differences in the recurrence of blood clots between the two groups. The trial will also look at other health outcomes, such as the development of post-thrombotic syndrome, which is a condition that can occur after a blood clot, and other vascular events like heart attacks or strokes.

Throughout the study, participants will be regularly checked to ensure their safety and to gather information on how the medication is affecting their health. The trial is expected to continue until the end of 2027, providing valuable insights into the potential benefits of Rosuvastatin Calcium for patients with these types of blood clots.